News

AstraZeneca has voluntarily withdrawn the Imfinzi (durvalumab) indication for adult patients who received treatment earlier in the US for locally advanced or metastatic bladder cancer. The company has

Biopharmaceutical company Dynavax Technologies (DVAX) has secured marketing authorisation from the European Commission (EC) for Heplisav B, a two-dose adult hepatitis B adjuvanted vaccine. The vaccine is used

Fast Track Designation is a process for facilitating the development and expediting the review of drugs to treat serious medical conditions. The novel and investigational factor VIII therapy

GlaxoSmithKline has signed an agreement with Vir Biotechnology to expand their Covid-19 collaboration to advance new therapeutics for influenza and other respiratory viruses. The company stated that the

Pfizer and BioNTech have entered into an agreement with the European Commission (EC) to supply an additional 200 million doses of their Covid-19 vaccine. The deal also includes

Swiss pharmaceutical company Novartis has secured the expanded US Food and Drug Administration (FDA) indication for Entresto, a Novartis therapy to treat patients diagnosed with guideline-defined heart failure.

Janssen-Cilag International, a subsidiary of Johnson & Johnson has submitted a conditional marketing authorisation application (cMAA) to the European Medicines Agency (EMA) for its investigational single-dose Janssen COVID-19

South Korean biopharmaceutical company Celltrion Healthcare has secured European Commission (EC) marketing authorisation for the sale of Yuflyma (CT-P17) for the treatment of multiple chronic inflammatory diseases. Yuflyma

The three partner sites in London, Southampton and Bristol. Building on earlier studies of the vaccine that have shown that it is safe, produces strong immune system responses and